Phase 1 · NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants
CompletedVerified
Registry record
Trial details
- Trial
- To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
- ClinicalTrials.gov ID
- NCT06808802
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 30
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Metoprolol
- Comparator
- Not reported
- Eligible ages
- 21 Years – 65 Years
- Locations
- 1 site · Singapore
- Study start
- 3 Feb 2025
- Primary completion
- 15 Apr 2025
- Study completion
- 15 Apr 2025
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 5 Jun 2025
Endpoints
Primary
Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol; Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide; PK: Maximum Concentration (Cmax) of Metoprolol; PK: Cmax of Metoprolol with Retatrutide
Secondary
Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)